Provitro stands at the forefront of histological innovation, specializing in the development of both manual and automated IHC staining protocols. Our capabilities extend to antibody target validation on normal and tumor tissues, leveraging our proprietary tissue bank. Ensuring the highest accuracy, our advanced in-process control system (iConTMA®) virtually elim- inates the risk of false-negative results. Beyond immunohisto- chemistry, Provitro offers a diverse suite of specialized servic- es, including in situ hybridization, digital pathology, N-Terminal sequencing, and bioassays (RUO/GLP), catering to the complex needs of cutting-edge research.